** Intuitive Surgical ISRG.O on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on growing demand for its surgical robots used in minimally invasive procedures

** At least two brokerages raised price targets, with BTIG reiterating its “Buy” rating and $616 PT, Leerink Partners lifting its PT to $622 and keeping “Outperform,” while Citi maintained its “Neutral” rating

EYES ON 2026 PROCEDURE GROWTH AND NEW SYSTEM ROLLOUT

** BTIG ("Buy", PT: $616) says procedure growth of about 18% in Q4 capped a strong year and expects the company’s 2026 procedure forecast to move higher as the year progresses

** Morningstar (PT: $378) says Intuitive ended the year strong but offered a cautious 2026 outlook, noting continued expansion in outpatient and ambulatory surgery centers

** Citi ("Neutral") says Q4 revenue and procedures were solid but notes pressure on profit margins from higher costs and tariffs, with management maintaining its 2026 targets

** Leerink Partners ("Outperform", PT: $622) says strong Q4 sales and earnings, growing use of the da Vinci 5 system, and expansion into cardiac and outpatient surgery support its view that 2026 forecasts are conservative, though it notes risks in China, Japan and Europe

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))